Europe Medical Isotope Production Market Size, Share & Trends Analysis Report By Isotope Type (Diagnostic Isotopes, Therapeutic Isotopes), By Production Technology (Nuclear Reactor-Based Production, Fission-based, Neutron activation, Cyclotron-Based Production), By Country (U.K., Germany, France, Spain, Italy, Russia, Nordic, Benelux) and Forecast, 2026-2034

Europe Medical Isotope Production Market Trends

Expansion of Theranostics and Modern Production Infrastructure

European isotope infrastructure is shifting toward higher-capacity reactors, cyclotrons, accelerator-driven systems, and targeted therapeutic radionuclides. Petten currently supports more than 30,000 patients per day, while its HFR is reported to produce approximately 70% of medical isotopes used in Europe and 30% globally. The planned PALLAS reactor is expected around 2030 with capacity exceeding 30,000 patients daily.

Technology investment increasingly targets both established Tc-99m supply and emerging Lu-177, Cu-67, Sc-47 and related theranostic radionuclides. More than 50 million nuclear-medicine procedures are performed annually worldwide, with Tc-99m involved in over 80% of diagnoses. Meanwhile, Belgium's MYRRHA accelerator-driven program targets medical-radioisotope output from 2027, illustrating diversification beyond conventional reactor routes.

Europe Medical Isotope Production Market Drivers

Rising Nuclear-Medicine Utilization and Oncology Requirements

Clinical utilization remains a principal expansion driver as more than 50 million nuclear-medicine procedures occur annually and Tc-99m supports over 80% of diagnostic procedures. Petten-origin isotopes alone serve more than 30,000 patients each day, while the HFR accounts for approximately 70% of European isotope production and around 30% globally. These utilization levels reinforce investment in Mo-99/Tc-99m continuity and therapeutic radionuclide capacity.

Europe Medical Isotope Production Market Restraints

Aging Reactor Fleet and Concentrated Supply Infrastructure

Supply concentration remains structurally restrictive because fewer than 6 reactors worldwide can manufacture medical isotopes at large scale, while one Petten facility represents about 70% of European production and 30% globally. Reactor outages can therefore affect thousands of daily procedures, and short isotope half-lives limit inventory buffering. Europe is simultaneously managing conversion, modernization, safety-review, and lifetime-extension programs across multiple research reactors.

Europe Medical Isotope Production Market Opportunities

New Reactors, Accelerators and Therapeutic Radionuclides

Infrastructure renewal creates substantial opportunities through PALLAS, MYRRHA, cyclotron expansion, and radioligand-therapy manufacturing. PALLAS is targeted around 2030 with capacity for more than 30,000 patients per day, while MYRRHA aims to provide medical radionuclides from 2027. In 2026, Curium also announced an investment exceeding EUR 32 million at Saclay, France, reinforcing European radiopharmaceutical capabilities.

Challenges in Europe Medical Isotope Production Market

Feedstock Security, Logistics and Capacity Transition

Europe must simultaneously replace aging infrastructure and secure nuclear feedstocks. Several reactors are transitioning toward HALEU-based operation, while strategic uranium materials remain dependent on imports. With fewer than 6 large-scale global production reactors and one European facility supplying approximately 70% of regional isotopes, even short interruptions can affect more than 30,000 patient-equivalent daily production capacity.

Europe Medical Isotope Production Market Segmentation

Segmentation covers isotope type, production technology, application, and end-user. Diagnostic isotopes dominate the quantified isotope category with approximately 58.5% of 2026 revenue versus 41.5% for therapeutic isotopes. Reactor- and cyclotron-based routes serve diagnostic, therapeutic, and research applications across hospitals, imaging centers, institutes, pharmaceutical companies, and CROs.

By Isotope Type

Diagnostic isotopes are the largest quantified subsegment, increasing from USD 763.96 million in 2025 to USD 832.79 million in 2026 and USD 1,660.61 million by 2034 at 9.01% CAGR. Their 2026 contribution is approximately 58.5%.

Therapeutic isotopes are the faster-expanding subsegment at 9.06% CAGR, rising from USD 541.07 million in 2025 and USD 590.09 million in 2026 to USD 1,180.98 million by 2034, supported by targeted radionuclide therapy.

By Production Technology

Production technology comprises nuclear reactor-based production, fission-based production, neutron activation, cyclotron-based production, proton acceleration, and deuteron-based reactions. The supplied dataset reports USD 1,422.88 million total isotope-type revenue in 2026 and USD 2,841.59 million in 2034, but does not provide technology-level values or CAGRs; therefore, no unsupported technology split is assigned.

Reactor systems remain critical for high-volume radionuclides, while cyclotrons and accelerator technologies broaden decentralized and specialty-isotope production. The supplied figures establish a 2025 total of USD 1,305.03 million and 2026 total of USD 1,422.88 million but do not identify the largest or fastest technology subsegment.

By Application

Applications comprise diagnostic, therapeutic, and research uses. Diagnostic isotope revenue of USD 832.79 million in 2026 provides an indicator of the scale of imaging-related supply, compared with USD 590.09 million for therapeutic isotopes; however, isotope-type figures cannot be treated as direct application revenues.

By 2034, diagnostic and therapeutic isotope revenues reach USD 1,660.61 million and USD 1,180.98 million respectively. Application-specific CAGR values were not supplied, preventing unsupported ranking of diagnostic, therapeutic, or research applications.

By End-User

Hospitals and clinics, diagnostic imaging centers, academic institutes, pharmaceutical and biotechnology companies, and CROs constitute the principal customer groups. The overall quantified base expands from USD 1,305.03 million in 2025 to USD 1,422.88 million in 2026.

The quantified isotope total reaches USD 2,841.59 million by 2034 at 9.03% CAGR. End-user-specific revenue and CAGR data were not provided, so numerical dominance among the 5 end-user categories is not inferred.

Europe Medical Isotope Production Market Counties Outlook

U.K.

The U.K. contributes approximately 20.0% in 2026, with revenue increasing from USD 261.01 million in 2025 to USD 284.29 million in 2026 and USD 563.15 million by 2034 at 8.92% CAGR.

Germany

Germany leads with approximately 28.4% in 2026. Revenue advances from USD 369.85 million in 2025 to USD 404.36 million in 2026 and USD 825.43 million by 2034 at 9.33% CAGR.

France

France contributes about 14.9% in 2026, rising from USD 195.75 million in 2025 to USD 212.64 million in 2026 and USD 412.33 million by 2034 at 8.63% CAGR.

Spain

Spain represents approximately 8.4% in 2026, expanding from USD 109.62 million in 2025 to USD 119.35 million in 2026 and USD 235.73 million in 2034 at 8.88% CAGR.

Italy

Italy accounts for approximately 10.0% in 2026. Revenue rises from USD 130.50 million in 2025 to USD 141.68 million in 2026 and USD 273.53 million by 2034 at 8.57% CAGR.

Russia

Russia contributes approximately 8.2% in 2026 and records one of the strongest trajectories, advancing from USD 107.14 million in 2025 to USD 117.26 million in 2026 and USD 241.49 million by 2034 at 9.45% CAGR.

Nordic

Nordic countries contribute approximately 5.0% in 2026, increasing from USD 65.90 million in 2025 to USD 71.80 million in 2026 and USD 142.54 million by 2034 at 8.95% CAGR.

Benelux

Benelux contributes approximately 5.0% in 2026 and records the highest country-cluster CAGR of 9.53%, moving from USD 65.25 million in 2025 to USD 71.47 million in 2026 and USD 148.04 million by 2034.

Top players in Europe Medical Isotope Production Market

• Curium Pharma
• NRG PALLAS
• Institut National des Radioéléments (IRE)
• Eckert & Ziegler
• POLATOM
• Orano Med
• ITM Isotope Technologies Munich
• Advanced Accelerator Applications
• Bayer
• Siemens Healthineers
• GE HealthCare
• Telix Pharmaceuticals

Top Two Companies

• NRG PALLAS

NRG PALLAS occupies a strategically important upstream position through Petten's isotope-production infrastructure. The HFR is reported to manufacture approximately 70% of Europe's medical isotopes and around 30% globally, providing a production-capacity proxy rather than a disclosed company revenue percentage. More than 30,000 patients are served daily from Petten-linked isotope output. The replacement PALLAS reactor is targeted around 2030 and is designed to preserve capacity exceeding 30,000 patients per day. Its 2025 multi-year Mo-99 agreement with Curium further strengthens continuity for Tc-99m, which is used in over 80% of more than 50 million annual nuclear-medicine diagnostic procedures worldwide.

• Curium Pharma

Curium maintains a leading European position across diagnostic and therapeutic radiopharmaceutical supply, although a verified Europe-wide company revenue percentage is not publicly disclosed in the reviewed sources. Its strategic exposure includes Tc-99m, a radionuclide involved in over 80% of more than 50 million annual nuclear-medicine diagnoses, alongside expanding PET and Lu-177 capabilities. During 2025, Curium extended its Mo-99 collaboration with NRG PALLAS, acquired Nucleis to expand European PET manufacturing, and completed the acquisition of Monrol to strengthen Lu-177 capacity. In June 2026, it announced more than EUR 32 million of investment in Saclay, France, reinforcing manufacturing infrastructure and its position across diagnostic and targeted therapeutic radiopharmaceuticals.

Recent Developments in Europe Medical Isotope Production Market

• 2026:Curium announced an investment exceeding EUR 32 million at Saclay, France, to strengthen its radiopharmaceutical capabilities.
• 2026:European Commission documentation indicated MYRRHA is expected to deliver medical radionuclides from 2027, while PALLAS is estimated to become operational around 2030.
• 2025:Curium and NRG PALLAS signed a new multi-year Mo-99 production agreement supporting Tc-99m continuity for a diagnostic isotope used in over 80% of more than 50 million annual procedures.
• 2025:Curium acquired Nucleis to expand European PET manufacturing capacity and completed its Monrol acquisition to increase Lu-177 and PET capabilities.
• 2025:PALLAS reported that Petten isotope production serves more than 30,000 patients daily, while the HFR supplies approximately 70% of European and 30% of global medical-isotope output.

Research Methodology

The analysis uses 2025 as the base year, 2026 as the current year, 2022–2024 as the historical period, and 2026–2034 as the forecast horizon. Mandatory supplied country and isotope datasets form the quantitative foundation, including USD 1,422.85 million in 2026 and USD 2,842.24 million in 2034. Country contributions were calculated directly from supplied 2026 values, while external institutional and company sources were used only for infrastructure, production-capacity, technology, competitive-positioning, and development context; unsupported segment or company percentages were not fabricated.